Correlates of drug use cessation among participants in the Canadian HIV-HCV Co-infection Cohort

Drug and Alcohol Dependence

Volumn 137, Issue 1, 2014, Pages 121-128

  Cox, Joseph ^a,b,c,d   Maurais, Emilie ^c   Hu, Lina ^a   Moodie, Erica E M ^a   Law, Stephanie ^a   Bozinoff, Nikki ^b   Potter, Martin ^a,b   Rollet, Kathleen ^b   Hull, Mark ^d,e   Tyndall, Mark ^d,f   Cooper, Curtis ^d,f   Gill, John ^d,g   Saeed, Sahar ^b   Klein, Marina B ^b,d  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c Montreal Health and Social Services Agency   (Canada)

^d Canadian HIV Trials Network   (Canada)

^e BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

^g Southern Alberta HIV Clinic   (Canada)

Author keywords

Crack cessation; Determinants of health; HIV HCV co infection; Injection drug use cessation

Indexed keywords

METHADONE;

ADULT; ALCOHOLISM; ARTICLE; CANADA; COHORT ANALYSIS; DEMOGRAPHY; DISEASE DURATION; DRUG ABUSE; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH PROGRAM; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MIDDLE AGED; MIXED INFECTION; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING; SOCIAL BEHAVIOR; CLINICAL TRIAL; COINFECTION; EPIDEMIOLOGY; HIV INFECTIONS; MULTICENTER STUDY; RISK FACTOR; SUBSTANCE-RELATED DISORDERS; TRENDS;

HEPATITIS C VIRUS; NICOTIANA TABACUM;

ADULT; CANADA; COHORT STUDIES; COINFECTION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; RISK FACTORS; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE-RELATED DISORDERS;

EID: 84896084139     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.01.014     Document Type: Article

References (79)

1. Adlaf, E.M., Begin, P., Sawka, E. (Eds.), Canadian Centre on Substance Abuse, 2005. Canadian Addiction Survey (CAS): A National Survey of Canadians' Use of Alcohol and Other Drugs: Prevalence of Use and Related Harms: Detailed Report. Ottawa, ON. Available at (accessed 3.10.11, archived by WebCite® at ). http://www.webcitation.org/62BsY2VWh.
2. Anglin M.D., Hser Y.I., Grella C.E. Drug addiction and treatment careers among clients in the Drug Abuse Treatment Outcome Study (DATOS). Psychol. Addict. Behav. 1997, 11:308-323.
3. Arnsten J.H., Demas P.A., Grant R.W., Gourevitch M.N., Farzadegan H., Howard A.A., Schoenbaum E.E. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J. Gen. Intern. Med. 2002, 17:377-381.
4. Baca C.T., Yahne C.E. Smoking cessation during substance abuse treatment: what you need to know. J. Subst. Abuse Treat. 2009, 36:205-219.
5. Bondy S.J., Rehm J., Ashley M.J., Walsh G., Single E., Room R. Low-risk drinking guidelines: the scientific evidence. Can. J. Public Health 1999, 90:264-270.
6. Booth R.E., Kwiatkowski C.F., Chitwood D.D. Sex related HIV risk behaviors: differential risks among injection drug users, crack smokers, and injection drug users who smoke crack. Drug Alcohol Depend. 2000, 58:219-226.
7. Bouhnik A.D., Carrieri M.P., Rey D., Spire B., Gastaut J.A., Gallais H., Obadia Y., Grp M.S. Drug injection cessation among HIV-infected injecting drug users. Addict. Behav. 2004, 29:1189-1197.
8. Bova C., Ogawa L.F., Sullivan-Bolyai S. Hepatitis C treatment experiences and decision making among patients living with HIV infection. J. Assoc. Nurses AIDS Care 2010, 21:63-74.
9. Bruggmann P. Accessing hepatitis C patients who are difficult to reach: it is time to overcome barriers. J. Viral Hepat. 2012, 19:829-835.
10. Bruneau J., Brogly S.B., Tyndall M.W., Lamothe F., Franco E.L. Intensity of drug injection as a determinant of sustained injection cessation among chronic drug users: the interface with social factors and service utilization. Addiction 2004, 99:727-737.
11. Carrieri M.P., Moatti J.P., Vlahov D., Obadia Y., Reynaud-Maurupt C., Chesney M. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. J. Epidemiol. Community Health 1999, 53:4-8. MANIF 2000 Study Group.
12. Celentano D.D., Galai N., Sethi A.K., Shah N.G., Strathdee S.A., Vlahov D., Gallant J.E. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001, 15:1707-1715.
13. Chevalier S., Fortin L. Community Health Indicators: Definitions and Interpretations 1995, Canadian Institute for Health Information, National Health Information Council.
14. Cornman J.C., Goldman N., Glei D.A., Weinstein M., Chang M.C. Social ties and perceived support: two dimensions of social relationships and health among the elderly in Taiwan. J. Aging Health 2003, 15:616-644.
15. Cornwell E.Y., Waite L.J. Social disconnectedness, perceived isolation, and health among older adults. J. Health Soc. Behav. 2009, 50:31-48.
16. Cox J., Morissette C., De P., Tremblay C., Allard R., Graves L., Stephenson R., Roy E. Access to sterile injecting equipment is more important than awareness of HCV status for injection risk behaviors among drug users. Subst. Use Misuse 2009, 44:548-568.
17. Davis G.L., Rodrigue J.R. Treatment of chronic hepatitis C in active drug users. N. Engl. J. Med. 2001, 345:215-217.
18. Dean A., Kolody B., Wood P., Matt G. The influence of living alone on depression in elderly persons. J. Aging Health 1992, 4:3-18.
19. DeBeck K., Kerr T., Li K., Fischer B., Buxton J., Montaner J., Wood E. Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. Can. Med. Assoc. J. 2009, 181:585-589.
20. Deren S., Kang S.Y., Colon H.M., Robles R.R. Predictors of injection drug use cessation among Puerto Rican drug injectors in New York and Puerto Rico. Am. J. Drug Alcohol Abuse 2007, 33:291-299.
21. Diggle P.J., Heagerty P., Liang K., Zeger S.L. Analysis of Longitudinal Data 2002, Oxford University Press Inc., New York.
22. Ding L., Landon B.E., Wilson I.B., Wong M.D., Shapiro M.F., Cleary P.D. Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. Arch. Intern. Med. 2005, 165:618-623.
23. Dowling-Guyer S., Johnson M.E., Fisher D.G., Needle R., Watters J., Andersen M., Williams M., Kotranski L., Booth R., Rhodes F., Weatherby N., Estrada A.L., Fleming D., Deren S., Tortu S. Reliability of drug users' self-reported HIV risk behaviors and validity of self-reported recent drug use. Assessment 1994, 1:383-392.
24. Evans J.L., Hahn J.A., Lum P.J., Stein E.S., Page K. Predictors of injection drug use cessation and relapse in a prospective cohort of young injection drug users in San Francisco CA (UFO Study). Drug Alcohol Depend. 2009, 101:152-157.
25. Fischer B., Haydon E., Rehm J., Krajden M., Reimer J. Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach-the case study of Canada. J. Urban Health 2004, 81:428-447.
26. Fleming C.A., Craven D.E., Thornton D., Tumilty S., Nunes D. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin. Infect. Dis. 2003, 36:97-100.
27. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
28. Goldstein M.F., Deren S., Magura S., Kayman D.J., Beardsley M., Tortu S. Cessation of drug use: impact of time in treatment. J. Psychoactive Drugs 2000, 32:305-310.
29. Grebely J., Genoway K.A., Raffa J.D., Dhadwal G., Rajan T., Showler G., Kalousek K., Duncan F., Tyndall M.W., Fraser C., Conway B., Fischer B. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend. 2008, 93:141-147.
30. Grebely J., Oser M., Taylor L.E., Dore G.J. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. J. Infect. Dis. 2013, 207(Suppl. 1):S19-S25.
31. Grebely J., Raffa J.D., Lai C., Krajden M., Kerr T., Fischer B., Tyndall M.W. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J. Viral Hepat. 2009, 16:352-358.
32. Hoff A.L., Riordan H., Morris L., Cestaro V., Wieneke M., Alpert R., Wang G.J., Volkow N. Effects of crack cocaine on neurocognitive function. Psychiatry Res. 1996, 60:167-176.
33. Hogg R.S., Yip B., Kully C., Craib K., O'Shaughnessy M.V., Schechter M.T., Montaner J. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. Can. Med. Assoc. J. 1999, 160:659-665.
34. Hser Y.I., Anglin M.D., Grella C., Longshore D., Prendergast M.L. Drug treatment careers. A conceptual framework and existing research findings. J. Subst. Abuse Treat. 1997, 14:543-558.
35. Jauffret-Roustide M., Le Strat Y., Couturier E., Thierry D., Rondy M., Quaglia M., Razafandratsima N., Emmanuelli J., Guibert G., Barin F., Desenclos J.-C. A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design. BMC Infect. Dis. 2009, 9:113.
36. Joseph A.M., Nichol K.L., Anderson H. Effect of treatment for nicotine dependence on alcohol and drug treatment outcomes. Addict. Behav. 1993, 18:635-644.
37. Klein M.B., Rollet K.C., Saeed S., Cox J., Potter M., Cohen J., Conway B., Cooper C., Cote P., Gill J., Haase D., Haider S., Hull M., Moodie E., Montaner J., Pick N., Rachlis A., Rouleau D., Sandre R., Tyndall M., Walmsley S. HIV and hepatitis C virus coinfection in Canada: challenges and opportunities for reducing preventable morbidity and mortality. HIV Med. 2013, 14:10-20.
38. Klein M.B., Saeed S., Yang H., Cohen J., Conway B., Cooper C., Cote P., Cox J., Gill J., Haase D., Haider S., Montaner J., Pick N., Rachlis A., Rouleau D., Sandre R., Tyndall M., Walmsley S. Cohort profile: the Canadian HIV-hepatitis C co-infection cohort study. Int. J. Epidemiol. 2010, 39:1162-1169.
39. Krentz H.B., Kliewer G., Gill M.J. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta Canada from 1984 to 2003. HIV Med. 2005, 6:99-106.
40. Lemon S.C., Friedmann P.D., Stein M.D. The impact of smoking cessation on drug abuse treatment outcome. Addict. Behav. 2003, 28:1323-1331.
41. Ly K.N., Xing J., Klevens R.M., Jiles R.B., Ward J.W., Holmberg S.D. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann. Intern. Med. 2012, 156:271-278.
42. Macias J., Palacios R.B., Claro E., Vargas J., Vergara S., Mira J.A., Merchante N., Corzo J.E., Pineda J.A. High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack. Liver Int. 2008, 28:781-786.
43. Mackesy-Amiti M.E., Ouellet L.J., Golub E.T., Hudson S., Hagan H., Garfein R.S. Predictors and correlates of reduced frequency or cessation of injection drug use during a randomized HIV prevention intervention trial. Addiction 2011, 106:601-608.
44. Marx K.A., Malka E.S., Ravishankar J., Schwartz R.M. Measurement of retention in care among adults infected with HIV in an urban clinic. AIDS Care 2011, 23:1298-1304.
45. McGowan C.E., Fried M.W. Barriers to hepatitis C treatment. Liver Int. 2012, 32(Suppl. 1):151-156.
46. McLaren M., Garber G., Cooper C. Barriers to hepatitis C virus treatment in a Canadian HIV-hepatitis C virus coinfection tertiary care clinic. Can. J. Gastroenterol. 2008, 22:133-137.
47. McMahon J.M., Tortu S. A potential hidden source of hepatitis C infection among noninjecting drug users. J. Psychoactive Drugs 2003, 35:455-460.
48. Mehta S.H., Genberg B.L., Astemborski J., Kavasery R., Kirk G.D., Vlahov D., Strathdee S.A., Thomas D.L. Limited uptake of hepatitis C treatment among injection drug users. J. Community Health 2008, 33:126-133.
49. Mehta S.H., Sudarshi D., Srikrishnan A.K., Celentano D.D., Vasudevan C.K., Anand S., Kumar M.S., Latkin C., Solomon S., Solomon S.S. Factors associated with injection cessation, relapse and initiation in a community-based cohort of injection drug users in Chennai, India. Addiction 2012, 107:349-358.
50. Metsch L.R., Pereyra M., Brewer T.H. Use of HIV health care in HIV-seropositive crack cocaine smokers and other active drug users. J. Subst. Abuse 2001, 13:155-167.
51. Meyer L., Wade A., Persoz A., Boué F., Dellamonica P., Caroli-Bosc C.N.C. Risk reduction and intravenous drug use abstinence in patients with HIV infection. Rev. Epidemiol. Sante Publique 1998, 46:34-39. The SEROCO group.
52. Myers R.P., Ramji A., Bilodeau M., Wong S., Feld J.J. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can. J. Gastroenterol. 2012, 26:359-375.
53. Myles A., Mugford G.J., Zhao J., Krahn M., Wang P.P. Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada. Can. J. Gastroenterol. 2011, 25:135-139.
54. National Institute of Health NIH consensus statement on management of hepatitis C. NIH Consens. State Sci. Statements 2002, 19:1-46.
55. Osilla K.C., Ryan G., Bhatti L., Goetz M., Witt M., Wagner G. Factors that influence an HIV coinfected patient's decision to start hepatitis C treatment. AIDS Patient Care STDS 2009, 23:993-999.
56. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus Infection. N. Engl. J. Med. 1998, 338:853-860. The HIV Outpatient Study Investigators.
57. Palepu A., Milloy M.J., Kerr T., Zhang R., Wood E. Homelessness and adherence to antiretroviral therapy among a cohort of HIV-infected injection drug users. J. Urban Health 2011, 88:545-555.
58. Persaud S., Tzemis D., Kuo M., Bungay V., Buxton J.A. Controlling chaos: the perceptions of long-term crack cocaine users in Vancouver, British Columbia, Canada. J. Addict. 2013, 10.1155/2013/851840.
59. Potter M., Yang H., Saeed S., Klein M. Cocaine and crack use and resulting lifestyle instability are linked to a reduced access to hepatitis C (HCV) treatments. 18th Annual Canadian Conference on HIV/AIDS Research 2009.
60. Public Health Agency of Canada, Division of Disease Surveillance, Bureau of Infectious Diseases, Laboratory Centre for Disease Control, 2000. Case Definitions of Diseases Under National Surveillance.Ottawa, ON. Available at (accessed 4.12.12, archived by WebCite® at ). http://www.webcitation.org/6CfxeIpB4.
61. Public Health Agency of Canada, Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada, 2006. I-Track: Enhanced surveillance of risk behaviours among people who inject drugs. Phase I Report, August 2006. Ottawa, ON. Available at (accessed on 3.10.11, archived by WebCite® at ). http://www.webcitation.org/62Bsae2GS.
62. Public Health Agency of Canada, Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, 2007. HIV/AIDS Epi Updates. Ottawa, ON. Available at (accessed 30.09.11, archived by WebCite® at ). http://www.webcitation.org/62BsNSYfn.
63. Public Health Agency of Canada, Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, 2011. Summary: Estimates of HIV prevalence and incidence in Canada, 2011. Ottawa, ON. Available at (accessed 20.12.12, archived by WebCite® at ). http://www.webcitation.org/6D40WKaZM.
64. Reed C., Bliss C., Stuver S.O., Heeren T., Tumilty S., Horsburgh C.R., Samet J.H., Cotton D.J. Predictors of active injection drug use in a cohort of patients infected with hepatitis C virus. Am. J. Public Health 2013, 103:105-111.
65. Richter K.P., Gibson C.A., Ahluwalia J.S., Schmelzle K.H. Tobacco use and quit attempts among methadone maintenance clients. Am. J. Public Health 2001, 91:296-299.
66. Richter K.P., McCool R.M., Catley D., Hall M., Ahluwalia J.S. Dual pharmacotherapy and motivational interviewing for tobacco dependence among drug treatment patients. J. Addict. Dis. 2005, 24:79-90.
67. Rodriguez-Penney A.T., Iudicello J.E., Riggs P.K., Doyle K., Ellis R.J., Letendre S.L., Grant I., Woods S.P. Co-morbidities in persons infected with HIV: increased burden with older age and negative effects on health-related quality of life. AIDS Patient Care STDS 2013, 27:5-16.
68. Roy E., Arruda N., Vaillancourt E., Boivin J.F., Morissette C., Leclerc P., Alary M., Bourgois P. Drug use patterns in the presence of crack in downtown Montreal. Drug Alcohol Rev. 2012, 31:72-80.
69. Samuels J.F., Vlahov D., Anthony J.C., Chaisson R.E. Measurement of HIV risk behaviors among intravenous drug users. Br. J. Addict. 1992, 87:417-428.
70. Shah N.G., Galai N., Celentano D.D., Vlahov D., Strathdee S.A. Longitudinal predictors of injection cessation and subsequent relapse among a cohort of injection drug users in Baltimore, MD 1988-2000. Drug Alcohol Depend. 2006, 83:147-156.
71. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 2005, 5:558-567.
72. Steensma C., Boivin J.-F., Blais L., Roy É. Cessation of injecting drug use among street-based youth. J. Urban Health 2005, 82:622-637.
73. Stoove M.A., Gifford S.M., Dore G.J. The impact of injecting drug use status on hepatitis C-related referral and treatment. Drug Alcohol Depend. 2005, 77:81-86.
74. Strike C.J., Gnam W., Urbanoski K., Fischer B., Marsh D.C., Millson M. Factors predicting 2-year retention in methadone maintenance treatment for opioid dependence. Addict. Behav. 2005, 30:1025-1028.
75. Swan D., Long J., Carr O., Flanagan J., Irish H., Keating S., Keaveney M., Lambert J., McCormick P.A., McKiernan S., Moloney J., Perry N., Cullen W. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. AIDS Patient Care STDS 2010, 24:753-762.
76. Tortu S., McMahon J.M., Pouget E.R., Hamid R. Sharing of noninjection drug-use implements as a risk factor for hepatitis C. Subst. Use Misuse 2004, 39:211-224.
77. Tourangeau R., Yan T. Sensitive questions in surveys. Psychol. Bull. 2007, 133:859-883.
78. van Ameijden E.J.C., Coutinho R.A. Large decline in injecting drug use in Amsterdam, 1986-1998: explanatory mechanisms and determinants of injecting transitions. J. Epidemiol. Community Health 2001, 55:356-363.
79. Word C.O., Bowser B. Background to crack cocaine addiction and HIV high-risk behavior: the next epidemic. Am. J. Drug Alcohol Abuse 1997, 23:67-77.